SCF Pharma Initiates Clinical Trial to Investigate the Anti-inflammatory Mechanism of Omega-3 Monoglycerides (MAG-SPM) and Enrolls Patients
Clinical Design and Mechanism of Action of Omega-3 Monoglycerides
Canadian bio-company SCF Pharma is conducting a clinical trial (NCT05161702) to evaluate the anti-inflammatory efficacy of Omega-3 Monoglycerides (MAG-Omega-3) based on its proprietary MAG-O3 technology. This study aims to elucidate how MAG-SPM, derived from omega-3 using soybean Lipoxygenase (LOX) enzymes, resolves inflammation. Researchers are analyzing the inhibitory effect of MAG-SPM on cell proliferation in peripheral blood mononuclear cells (PBMCs) isolated from healthy donors after treatment with lipopolysaccharide (LPS), an inflammatory inducer.
Clinical Trial Progress and Timeline
This study officially commenced on March 12, 2019, with the enrollment of the first patient, and is currently actively recruiting participants at the IRCL (Institut de recherche en clinique et en santé Laval) in Quebec, Canada. It is designed as an observational study involving the collection of blood samples from a total of 200 healthy adults, with a primary completion date of December 31, 2026, and a final study completion date of January 1, 2027. Participants undergo strict screening, including a strict restriction on the use of anti-inflammatory drugs such as aspirin and ibuprofen, and omega-3 dietary supplements, starting seven days before clinical participation.
Trends and Competitive Landscape of the Global Prescription Omega-3 Market
The global prescription Omega-3 market is currently valued at approximately $1.4 billion to $1.6 billion as of 2025, with a steady growth rate of 6% to 8% per year. This market is led by Amarin's high-purity EPA formulation, Vascepa (2025 revenue of approximately $213.6 million), and GSK's Lovaza. However, existing ethyl ester (EE) formulations have a critical limitation of low bioavailability in the human body. The monoglyceride (MAG) form developed by SCF Pharma is absorbed immediately without pancreatic lipase digestion, significantly improving bioavailability and is considered a game-changer with the potential to reshape the market.
SCF Pharma's Business Model and Future Prospects
SCF Pharma has established a business model of licensing its proprietary MAG-O3 and MaxSimil platform technologies to multinational healthcare companies. Atrium Innovations, a subsidiary of Nestle Health Science, has successfully commercialized these technologies. This clinical study is a strategic move to expand the pipeline beyond simple dietary supplements to specific anti-inflammatory mediators (SPMs), and is expected to provide new therapeutic options for patients with chronic inflammatory diseases.
Potential for Expansion into Cellular Senescence and Biological Age Research
This clinical trial not only aims to suppress inflammatory responses but also explores the possibility of restoring cellular senescence and biological age. Chronic inflammation is a key factor that accelerates aging, and fundamentally 'resolving' inflammation is a critical issue in the field of anti-aging medicine. Based on this mechanism research, SCF Pharma aims to strengthen its next-generation functional pharmaceutical and health supplement product lines targeting the elderly population, which is expected to serve as a long-term cash cow in an aging society.
This clinical trial is significant in the global prescription Omega-3 market, valued at $1.4 to $1.6 billion in 2025, as it attempts to overcome the bioavailability limitations of existing ethyl ester formulations. From an investor's perspective, it presents an opportunity to re-evaluate the platform technology value of SCF Pharma, which has commercially validated its proprietary MaxSimil technology by licensing it to global food, beverage, and pharmaceutical companies such as Nestle. In the research and development industry, the study focuses on a new anti-inflammatory mechanism that converts omega-3 into specific anti-inflammatory mediator (SPM) monoglycerides through soybean Lipoxygenase (LOX) enzyme treatment. In the short term, the goal is to elucidate the mechanism through the analysis of donor PBMC samples, and in the medium to long term, it is expected that the commercialization of a highly effective pipeline for overcoming chronic inflammatory diseases will be accelerated based on the data from this observational clinical trial.
Source: ClinicalTrials.gov (api_ct)